

Index

A

ACT. *See* Adoptive cell therapy
Adoptive cell therapy (ACT), 212
Ahr, 52
AIRN, 133
Alemtuzumab, 49
AMPK, 166, 168, 170
AP-1, 119–120

B

BATF, 9
Batf3, 205
BAZ1B, 170
Bcl-2, 317, 352
Bcl2l11, 139
Bcl6, 8, 118, 187, 288–289, 291
Bhlhe4, 52
BIM, 294
Blimp1, 8–9, 38, 52, 99, 117–118, 187,
203, 229–230, 246, 289, 291
BTG1, 74
BTG2, 74
BZLF-1, 41

C

C3P0, 170
CASPASE3, 294
Cbx3, 122
CCL2, 261
CCL3, 94
CCL4, 94
CCL5, 65
CCL7, 261
CCL19, 93
CCL21, 93
CCL25, 226
CCR4, 94, 96, 205
CCR5, 66, 94, 99, 275
CCR7, 2, 22–23, 33–34, 36, 38, 66, 91, 93,
99, 184, 206, 223, 230, 241, 269,
272, 289, 302–304, 312
CCR8, 205
CCR9, 53–54, 335
CCR10, 96, 205

CD5, 36–37, 313–314, 318
CD11a, 228, 242
CD11c, 98
CD24, 273
CD25, 194, 316, 318, 352
CD26L, 5
CD27, 33–34, 36, 110, 173, 192, 303, 315
CD28, 8, 34, 36, 166, 303, 315, 355
CD31, 36
CD39, 49
CD43, 110
CD44, 1, 28–29, 67–68, 110, 302–304, 312, 317–319
CD45.1, 26, 185
CD45.2, 26, 185
CD45RA, 2–4, 28, 33–37, 41, 67, 268, 302–304
CD45RO, 3, 28, 34, 36, 268, 332
CD49a, 57, 242, 246, 270
CD49b, 335
CD49d, 67, 318
CD57, 41
CD62L, 2, 10, 22, 34, 36, 38, 66, 68, 91, 93, 97, 99, 110,
122–123, 158, 184, 192–193, 230,
240–241, 258, 269, 273, 302, 305, 312
CD69, 4, 9, 48–49, 56–58, 98, 202–203, 206, 208,
224, 227, 230, 232, 242, 246, 260, 270,
318, 335–336
CD80, 320, 355
CD85j, 41
CD86, 320, 355
CD90.1, 185
CD90.2, 185
CD95, 303
CD103, 4, 9, 36, 48–49, 51, 56–58, 96, 98, 101,
202–203, 206–208, 224, 227–232,
242–243, 246, 270, 277
CD122, 10, 67, 302, 334
CD127, 38, 54, 110–111, 118, 122, 130, 158, 167,
192–193, 205, 271, 350
CD137, 159
Central memory T cell (T_{cm}), 2–3, 27–28, 188
Chromatin remodeling. *See* Epigenetics
CLA, 53, 335
c-Myb, 9
COVID-19, 140
CPT1a, 166–168

Index

- CTACK, 226
CTLA4, 10, 43, 212, 320
CX3C, 52
CX3CR1, 1, 5, 12, 23, 52, 56, 66, 92, 98, 100, 110, 172, 223, 269, 276–277, 279
CXCL9, 55–56, 95, 98–99, 205, 224, 275
CXCL10, 55–56, 95, 98–99, 205, 224, 275
CXCL11, 95
CXCL13, 42
CXCR3, 40, 55, 66, 95, 98–100, 110, 205, 224, 226, 242, 275, 352
CXCR4, 97, 101
CXCR5, 12, 24, 41, 174–175, 288–290, 292–293, 295, 355
CXCR6, 57, 95–96, 242
- D**
DC. *See* Dendritic cell
Dendritic cell (DC), 8, 48, 50, 53, 58, 93, 95–98, 138, 150–151, 205, 210, 218, 228, 243, 245–247, 249, 260, 262, 273, 276, 313, 317, 319
DHFR, 133
DNDR1, 53, 58
- E**
EBNA proteins, 41
EBV, 304
Effector CD8 T cell
 developmental regulation, 8–9
 disappearance during contraction phase, 293–294
 heterogeneity
 cell pools, 4–8
 mechanisms producing heterogeneity, 289–291
 primary immune response cells, 288–289
 multilineage priming and lineage bias, 115–116
 overview, 1–2, 110
 specification mechanisms, 291
 subsets, 2–4, 111–112
 supergroups, 28
Effector memory RA T cell (Temra), 3
Effector memory T cell, 3
EOMES, 38, 52, 67, 100, 122
Epigenetics
 chromatin changes in memory T-cell formation, 70–73
 chromatin remodeling and lineage restriction of effector and memory cell subsets
 chromatin structure, 120
 differential activity of enhancers and transcription stabilizes terminal and memory subsets, 120–121
 reversible chromatin modification and lineage interconversion, 122–123
 transcription factors and lineage stability in mature memory cells, 121
 transcriptional silencing and terminal differentiation, 121–122
 chromatin remodeling and transcriptional reprogramming during memory T-cell formation
 chromatin accessibility, 118–119
 naive cell activation and multilineage potential, 119–120
 fate commitment of T cells, 156–160
 long noncoding RNA and lymphocyte memory. *See* Long noncoding RNA
 T-cell differentiation, 13, 305–307
Epithelial tissue-resident memory T cell.
 See Tissue-resident memory T cell
Exhausted T cell (Tex)
 exhaustion mechanisms, 10–11
 overview, 4, 42
 precursors, 13
 subsets
 intermediate cells, 12
 progenitor cells, 11–12
 terminal cells, 12
Ezh2, 122, 139, 159
- F**
Fabp4, 167
FABP4, 57
Fabp5, 167
FABP5, 57
FAO, 166–168
Flatr, 139
Flicr, 139
Fos, 9
FOXO1, 38, 99–100, 156
Foxp3, 139, 158
FTY720, 202, 334
- G**
GAS5, 133, 140
GATA3-ASI, 137
GM-CSF, 270
GPR18, 97
GZMA, 38
GZMB, 38, 116, 210

- H**
- H1N1, 66
 - Hematopoietic stem cell (HSC), 185
 - HIF-1 α , 167
 - HIV, 306
 - Hobit, 9, 52, 100, 203, 229, 246
 - HOTAIR*, 133, 137
 - HOXD*, 133
 - HSC. *See* Hematopoietic stem cell
 - HSV-1, 241, 244
 - HSV-2, 209
- I**
- ICOS, 289, 348, 355
 - ICOSL, 348
 - Id2, 8, 100, 116, 121, 137, 156, 187
 - Id3, 8, 116, 118, 137, 187
 - IFNG-AS1*, 139
 - IFN- γ , 3, 8, 22, 24–26, 36–38, 51–53, 56, 68–69, 101–102, 131, 137–138, 152, 157, 172–174, 206, 209–210, 220, 241, 244, 247–248, 256, 261, 268–275, 288, 289, 292–293, 301–303, 318, 321, 354
 - Igfr2*, 134
 - IL-1, 256
 - IL-2, 68–69, 117, 152, 172, 192, 194, 208, 210, 231, 268, 273, 291, 301, 315, 317, 322, 333, 350–352
 - IL-4, 26, 73, 232
 - IL-5, 211, 232
 - IL-7, 25–26, 54, 57, 67, 97, 99, 101, 243, 276–277, 314–316, 320, 322, 333, 337, 340–341
 - IL-7R, 157, 294
 - IL-10, 24, 117, 247, 257
 - IL-12, 117, 131, 244, 273, 291, 321
 - IL-13, 211, 232, 321
 - IL-15, 25–26, 57, 67–68, 97, 100–101, 166, 168, 207–208, 228, 231, 243, 273, 276–277, 316–317, 319–322, 333, 337, 340–341, 350–351
 - IL-17, 211
 - IL-18, 131, 211
 - IL-21, 117, 172, 315
 - IL-22, 270
 - IL-33, 232, 245
 - Influenza
 - influenza-specific lung tissue-resident memory T cell
 - decline, 246–249
 - generation, 244–246
 - overview, 244
 - vaccine induction, 249
 - memory CD4 T-cell studies, 354–357
 - public health burden, 239–240
 - strains, 239
 - vaccination, 240, 356–357
 - IRF4, 9, 291
 - ITAM, 176
- J**
- Jun, 9
- K**
- KCNQ1OT1*, 133
 - Ki-67, 39, 41, 56
 - KLF2, 9, 38, 52, 56, 99, 206, 209, 230, 242–243, 272, 289, 334, 336
 - KLGR1, 1, 3–4, 36, 38–39, 52–55, 84, 92, 97, 100, 110–111, 115–119, 121, 167, 192–193, 205, 207, 271, 277
- L**
- LAG3, 10, 42, 212
 - LCMV. *See* Lymphocytic choriomeningitis virus
 - LDHA, 170
 - LEF1, 38, 289
 - Leishmaniasis
 - immune response, 256–257
 - persistent infection in immune maintenance, 257
 - prospects for study, 262–263
 - tissue-resident memory T cells
 - generation, 257–258
 - protection against infection, 259–261
 - vaccination, 261–262
 - LFA-1, 98, 206, 228, 270
 - Listeria monocytogenes*, 39, 49, 151, 158, 288
 - lncRNA. *See* Long noncoding RNA
 - Long noncoding RNA (lncRNA). *See also specific RNAs*
 - characteristics, 132–133
 - COVID-19 studies, 140
 - epigenetic control of memory and adaptation, 130–132
 - gene expression regulation, 133–134
 - immune cell functions, 134–139
 - LSD1, 139
 - Lung tissue-resident memory T cell. *See* Tissue-resident memory T cell
 - Ly6C, 289, 293, 295
 - Lymphocytic choriomeningitis virus (LCMV), 68, 111, 115, 119, 130, 140, 158, 172, 174, 207–208, 229, 244, 256, 275, 288–289, 291, 301–302, 306

Index

M

- Maf*, 139
MALAT1, 133
MCMV. *See* Murine cytomegalovirus
Memory CD4 T cell
 generation
 effector cell costimulation and APC recognition, 351–352
 IL-2 as effector checkpoint, 350–351
 TCR signaling at effector checkpoint, 352–354
 influenza infection studies, 354–357
 overview, 348
 prospects for study, 357
 subsets, 349–350
Memory CD8 T cell
 acute infection and formation, 113–114
 classification, 2–4, 111–112, 268–270
 compartmentalization
 overview, 332
 tissue and blood, 332–336
 conditional survival versus intrinsic half-life, 338–341
 developmental regulation, 8–9
 differentiation
 effector T-cell diversification, 271–272
 model of generation, 294–295
 overview, 270–271
 regulating factors
 lymph nodes, 272–273
 peripheral tissue, 273, 275
 formation and heterogeneity, 291–293
 heterosubtypic immunity, 240–241
 maintenance
 overview, 316–317
 subsets
 cytokines, 276–277
 homeostasis during quiescence, 275–276
 recurrent pathogen encounters, 277–278
 markers, 302–305
 metabolism. *See* Metabolism, memory T cell
 multilineage priming and lineage bias, 115–116
 overview, 1–2, 110
 persistence, 336–338
 potential during secondary responses, 293
 single-cell studies of fate determination. *See* Single-cell studies, memory T cell
 supergroups, 28
 tissue residency. *See* Tissue residency;
 Tissue-resident memory T cell
Memory-phenotype (MP) T cell
 definition, 317–318
 function, 321–322
 generation, 318–320
 maintenance, 320–321
 prospects for study, 322
Memory stem T cell (Tscm), 3–4, 10
Metabolism, memory T cell
 cell fate decisions, 170–172
 overview, 165–167
 prospects for study, 176
 signaling networks for cell development, 167–170
 stemness studies
 balancing stemness with exhaustion, 174–176
 metabolic features, 172–174
Mm47, 134
MP T cell. *See* Memory-phenotype T cell
mTORC1, 167–168
mTORC2, 167
Murine cytomegalovirus (MCMV), 207, 229
Myo9b, 224
- ### N
- Naive T cells
 antigen-specific memory cell generation, 315–316
 chromatin remodeling and transcriptional reprogramming during memory T-cell formation, 119–120
 fate imprinting of tissue-resident memory T cell, 50–51
 IL-7 signaling, 314–315
 TCR signaling, 313–314
NEAT1, 133
NEST, 139
NFAT, 137
NKG2A, 67
NKILA, 137
Notch, 246
Nr4a1, 52, 206, 307
NRON, 137
- ### O
- OT-11, 352
- ### P
- P2RX7, 55, 57, 170, 207, 230–231, 291
PACER, 137
PANDA, 133
PD-1, 4, 10–13, 24, 42, 57, 87, 152, 175, 212, 245, 248, 288–289, 292, 355
PD-L1, 248

PD-L2, 248
 PEpCK, 262
 Peripheral memory T cell (Tpm), 92
 Pfp, 65
Prdm1, 118, 121
PRF1, 123
 PRF1, 38
 PSGL1, 289, 293
 PSIP1, 170
Ptgs2, 137
Pvyl, 140

R

RAG, 319–320
 Regeneration, T cells
 failure, 86–87
 heterogeneity among differentiated lineages,
 84–85
 layered adaptive immunity, 81–83
 prospects for study, 87
 specification and determination, 83–84
 TCF1 as marker, 85
 three-layered schema, 85–86
 RIG-I, 139
 RSV, 244
 RUNX, 119–120
 RUNX3, 51–52, 100, 118, 206–207, 229

S

S1PR1, 48, 56, 96, 98, 206, 209, 242, 260,
 268, 270, 272, 334–336
 SAP, 348
Sell, 121, 157
 SGP-1 phosphatase, 313
 Single-cell studies, memory T cell
 averaging of single-cell behaviors, 189–190
 developmental framework, 192–193
 division speed and early segregation into
 precursors, 193–194
 multiple fates, 187–188
 probabilistic variation, TCR-determinism, and
 immunodominance hierarchies,
 191–192
 prospects for study, 194–195
 stemness of central memory T cells, 188
 techniques, 184–187
 SOCS3, 117
 SOD2, 294
Sros1, 137
Stat1, 137
 STAT1, 289
 STAT3, 117, 257, 337, 352

T

T-bet, 8, 52, 67, 99, 117, 187, 206, 289, 291–293
 TBX21, 38, 100, 121
 TCF1, 8, 10–13, 24, 71, 83–86, 116, 118, 168,
 173–176, 187, 193, 272, 289
Tcf7, 38, 71, 116, 118, 122, 206
 Tcm. *See* Central memory T cell
TEA, 137
 Temra. *See* Effector memory RAT cell
Tet2, 123
 TET2, 9
 Tex. *See* Exhausted T cell
 TFIIB, 133
 TGF- β , 8, 10, 26, 40, 50–51, 56–58, 95–96, 98,
 101–117, 139, 205–208, 227–232,
 242–248, 278, 319, 340, 350
THRIL, 137
 TIGIT, 10, 43
 TIM3, 10, 12, 42, 212
 Tissue residency. *See also* Tissue-resident memory
 T cell
 heterogeneity of tissue-resident memory T cells,
 207–208
 immunotherapy, 211–213
 imprinting and regulation of tissue-resident
 memory T cells, 203–207
 overview, 201–203
 prospects for study, 213
 tissue memory in immune protection and
 pathology, 208–211
 Tissue-resident memory T cell (T_{rm}).
 See also Tissue residency
 characteristics, 47–48, 202–203
 epithelial cells
 adaptation, 227–228
 intraepithelial migration, 224–227
 overview, 224
 unique features, 228–229
 fate-imprinting signals prior to tissue entry
 preconditioning of naive cells, 50–51
 priming signals, 51–54
 functional overview, 243–244
 generation and maintenance, 241–243
 heterogeneity, 207–208
 heterogeneity, 54
 imprinting and regulation, 203–207
 influenza-specific lung cells
 decline, 246–249
 generation, 244–246
 overview, 244
 vaccine induction, 249
 leishmaniasis skin-resident cells
 generation, 257–258

Index

- Tissue-resident memory T cell (Trm) (*Continued*)
 protection against infection, 259–261
 maintenance, 56–57
 overview, 4, 9–10, 23, 67, 241
 precursor, 54
 prospects for study, 232–233
 protective function, 48–50
 stromal cells
 development, 229–230
 overview, 229
 subpopulations
 CD4 cells, 231–232
 CD8 cells, 230–231
 therapeutic targeting, 57–58, 211–213
 tissue entry, 54–56
 tissue retention, 56
 trafficking, 92
 transcription factors in formation, 52
Tox, 307
Toxoplasma gondii, 93, 321
Tpm. *See* Peripheral memory T cell
TRAF6, 166
Trafficking, memory T cells
 cell subsets, 91–92
 prospects for study, 101–102
 spatiotemporal regulation
 maintenance and reactivation, 97–99
 priming and effector differentiation, 92–97
 transcriptional regulation of effector and memory
 differentiation, 99–101
Trm. *See* Tissue-resident memory T cell
Trypanosoma cruzi, 258, 262
Tsc1, 167
Tsc2, 167
Tscm. *See* Memory stem T cell
Tvm. *See* Virtual memory T cell

V
Vaccination
 influenza, 240, 356–357
 leishmaniasis, 261–263
 yellow fever, 9
Vaccinia virus (VV), 93–94
Vesicular stomatitis virus (VSV), 93
VHL, 167, 172
Virtual memory T cell (Tvm), 67–68
VISTA, 74
VLA-1, 98, 206
VSV. *See* Vesicular stomatitis virus
VV. *See* Vaccinia virus

X
XBP1, 175
Xist, 134

Y
Yellow fever virus (YFV)
 T-cell response, 302–333
 vaccine, 9
YFV. *See* Yellow fever virus
YY1, 134

Z
Zeb2, 8, 100, 117, 121
Zfp292, 139